[HTML][HTML] Improvement of medical treatment in japanese patients with metastatic renal cell carcinoma
R Fujiwara, Y Komai, T Oguchi, N Numao… - Cancer Diagnosis & …, 2022 - ncbi.nlm.nih.gov
R Fujiwara, Y Komai, T Oguchi, N Numao, S Yamamoto, J Yonese, T Yuasa
Cancer Diagnosis & Prognosis, 2022•ncbi.nlm.nih.govResults Median OS and one-, three-and five-year OS rates were not reached and 88.7%,
64.9%, and 64.9% in patients treated in 2016-2020; 31.4 months and 78.5%, 42.8% and
34.2% in 2008-2015 (p= 0.0013). Multivariate analysis identified the period in which first-line
therapy was started as the strongest predictor for OS (p= 0.0002). Conclusion OS was
significantly better in mRCC patients treated in 2016-2020 than in 2008-2015. Treatment
period was the strongest predictor for OS.
64.9%, and 64.9% in patients treated in 2016-2020; 31.4 months and 78.5%, 42.8% and
34.2% in 2008-2015 (p= 0.0013). Multivariate analysis identified the period in which first-line
therapy was started as the strongest predictor for OS (p= 0.0002). Conclusion OS was
significantly better in mRCC patients treated in 2016-2020 than in 2008-2015. Treatment
period was the strongest predictor for OS.
Results
Median OS and one-, three-and five-year OS rates were not reached and 88.7%, 64.9%, and 64.9% in patients treated in 2016-2020; 31.4 months and 78.5%, 42.8% and 34.2% in 2008-2015 (p= 0.0013). Multivariate analysis identified the period in which first-line therapy was started as the strongest predictor for OS (p= 0.0002).
Conclusion
OS was significantly better in mRCC patients treated in 2016-2020 than in 2008-2015. Treatment period was the strongest predictor for OS.
ncbi.nlm.nih.gov
以上显示的是最相近的搜索结果。 查看全部搜索结果